|

A Deep Dive Into MindMed’s Microdosing Program: Project Flow | Plus a NEW LSD Microdosing Study

ByPsychedelic Spotlight

In today’s episode, we look at MindMed’s (Nasdaq: MNMD, NEO: MMED) Project Flow, which is their LSD microdosing division. At present, MindMed’s microdosing program is split into 2 projects: base testing of LSD microdoses in healthy individuals, and using LSD microdoses to treat adult ADHD.

We will explore the progress made on both fronts, and where the program will expand to in the future, such as psilocybin (magic mushrooms) microdosing.
Ultimately, MindMed wants to answer questions such as:

Can microdosing psychedelics treat ADHD?
Can microdosing LSD improve your concentration?
Can microdosing decrease your anxiety?
Does microdosing increase creativity?
Does microdosing improve your mood?

Recently MindMed announced they are ready to begin recruiting for a study testing the variations in effect when taking LSD microdoses in the morning, compared to at night. The study will also try to answer the last four above questions. We discuss this study extensively.

Links:
MindMed Project Flow: https://mindmed.co/psychedelic-inspired/#scroll_section-2
MindMed New study: https://psilocybinalpha.com/news/mindmed-launches-study-of-low-dose-lsd-effects-on-sleep-and-cognitive-measures

Imperial College of London study: https://www.theguardian.com/science/2021/mar/02/microdosing-lsd-benefits-might-be-placebo-effect-study-finds

Project Albert Quote: https://mindmed.co/news/press-release/mindmed-expands-psychedelic-microdosing-division-adds-groundbreaking-study-evaluating-lsd-microdosing-through-next-gen-digital-clinical-markers/

Kim Kuypers Study: https://www.nature.com/articles/s41598-021-01811-4

MindMed Investor’s Deck: https://mindmed.co/wp-content/uploads/2021/11/MindMed-Presentation-11.17-compressed.pdf

LSD for ADHD: https://mindmed.co/news/press-release/mindmed-advances-phase-2-lsd-microdosing-trial-for-adult-adhd-appoints-principal-investigator/
https://mindmed.co/news/press-release/mindmeds-microdosing-division-further-expands-phase-2-clinical-trial-of-microdosing-lsdfor-adult-adhd/

Previous MindMed LSD study: https://mindmed.co/news/press-release/mindmed-announces-the-completion-of-phase-1-study-measuring-dosing-effects-of-lsd/

Enjoy the episode!

Follow us on social media!
Instagram: @thepsychedelicinvestor
Facebook: @thepsychedelicinvestor
James’ Twitter: @Psy_Invest
Maria’s Twitter (Producer & Editor): @Psy_Holy
Want to collaborate? Send us an email at:
thepsychedelicinvestor@gmail.com

Music from:
www.bensound.com

Video editing: @themyaholy

DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.

#Mindmed #MNMDstock #Microdosing

Similar Posts

  • BIG NEWS on MindMed’s Clinical Trials [ Important MMED/MMEDF UPDATES You Need to Know ]

    Listen, Videos

    Hello Psychedelic Investors! Today, we will focus on MindMed’s 2021 Investors Deck and Project Lucy & Project Layla’s clinical trials updates.
    MindMed, ticker symbol MMED on the Canadian NEO Stock exchange, and MMEDF on the American OTC Market has updated their 2021 Investors Deck (TWICE) in this year. As a fellow MindMed geek, I did my due diligence to compare the information on both decks and there’s a few clinical trial changes and a few other updates I found important to discuss.

    In this episode, we will discuss:

    Timecodes
    0:00 – Intro
    3:02 – MindMed’s Project Lucy Updates
    6:27 – MMED’s18-MC And Microdosing Updates
    9:00 – LSD to treat Suicide Headaches
    11:04 – Phase 1 Updates
    14:06 – Stats Updates
    15:32 – MindMed Stock Speculation Zone

    Important to mention that after we shot this video, MindMed did answer our inquiry about the removed readout with “Hello – Sorry for the delay. We plan on filing the IND for Project Lucy in Q3 of 2021.”
    I’m not sure if that means that there will be a readout in Q3 as well…

    I hope you guys found some value in this and I’ll keep you posted for more changes!

    Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!

    Follow us on social media! 🙌
    Instagram: @psychedelicinvestor
    Facebook: @thepsychedelicinvestor
    Music: www.bensound.com
    Video by Pressmaster from Pexels

    DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.

    #MindMed #MMEDF #MindmedStock

  • Can DMT Treat Depression?

    Learn, Videos

    Welcome to the Psychedelic Spotlight podcast. In this episode, the Psychedelic Investor sits down with Dr. Carol Routledge, Chief Scientific and Chief Medical Officer of Small Pharma (TSX.V: DMT, OTC: DMTTF). Dr. Carol Routhledge is an expert in psychedelic medicines, and she specializes in DMT.

    In this interview, we attempted to answer the following questions:

    What happens when you take DMT?

    Can DMT help with depression?

    Is DMT safe?

    Small Pharma is a company that I am very excited about, as they are focussing on the psychedelic DMT, which I believe to have unlimited potential as a mental health drug.

    Small Pharma is currently running a phase 2 Clinical Trial Attempting to treat Major Depressive Disorder using DMT, the world’s furthest progress DMT Study. We can expect results by the end of the year. If they are successful, the company will begin a phase 3 trial.

    #DMT #SmallPharma #depression

  • The Biggest Psychedelic News This Week – October 23rd

    Learn, Research

    As researchers investigate the potential of psilocybin in cancer patients and LSD as treatment for ADHD, the psychedelic ecosystem witnesses more acquisitions, patents, and decriminalization efforts. However, the space also sees reprimands for abuse by therapists and a pilot attributing almost shutting off plane engines to a “nervous breakdown” caused by shrooms.

  • Is ‘The Trip’ Essential to The Psychedelic Experience?

    Learn, Research

    Biology and experience are tough to separate, but some researchers are exploring the possibility of non-hallucinogenic psychedelics as a mental health treatment. This begs the question: what do we lose, and what do we gain when we take the trip out of the psychedelic experience?